Stroke etanercept injection 18 months on: what lasted, what changed, and what Andrew learned after the PESTO trial
Some stroke survivors are told a version of the same sentence in hospital: “After three months, what you have is what you’ll have.”
Andrew Stops didn’t buy it, not because he was naïve, but because he needed a reason to keep showing up for rehab when nobody could give him a straight answer about what “recovery” would look like.
Four years after his ischemic stroke, and 18 months after a stroke etanercept injection, Andrew is back to share what improved quickly, what continued to evolve, and how he made peace with research results that didn’t match his lived experience.
The question so many survivors are really asking
When people reach out about perispinal etanercept (often discussed as “etanercept after stroke”), they’re rarely asking for a science lecture.
They’re asking:
- Will this help me get my life back?
- Will I be the person it works for… or the person it doesn’t?
- How do I decide without being misled by hype, fear, or my own desperation?
Those questions are valid. They’re also heavy, because the stakes are high: the treatment is expensive, travel can be intense, and the emotional cost of hoping—then not getting results—can be brutal.
Andrew’s baseline: what his stroke took at the start
Andrew’s stroke most impacted his right side. Early on, he had:
- No use of his right arm or hand
- A weaker right leg
- Right foot drop
- A slight speech impediment
He worked hard to walk again quickly, using practical supports early (including an elastic extension on his shoe to help keep his foot up). But his bigger mission was clear: find ways to complement rehab—because medical staff couldn’t give him a timeline, and he felt a “lack of hope” from their perspective.
That’s a common moment for survivors: you’re doing the work, but you also want a map.
The “complement” phase: why hyperbaric helped, even without perfect measurement
Before etanercept entered the picture, Andrew leaned on what had helped him before: hyperbaric oxygen therapy (HBOT). He had a history of a brain tumor and had used hyperbaric previously for healing, so he rented a soft-shell chamber at home for three months and went in daily for 90 minutes.
Andrew was careful with his claims: he couldn’t measure physiological changes in real time at home. But he could measure something important, his ability to cope.
HBOT became a daily “warm cocoon” where he could breathe oxygen-rich air and calm his nervous system. For him, that mental-health benefit wasn’t a side note. It was fuel.
And when you’re rebuilding your life after stroke, fuel matters.
The etanercept decision: hope, uncertainty, and the reality of the “roll the dice” problem
Andrew discovered perispinal etanercept through a media story about Dr. Tobinick’s clinic, and after about a year, decided he needed to know he’d tried everything he reasonably could.
He crowdfunded to afford the trip and treatment.
That detail matters because it introduces the single biggest ethical challenge around treatments like this:
Even if you try to stay balanced, it’s hard not to hang hope on something that costs time, money, energy, and pride.
Andrew doesn’t tell people to go. In fact, when people contact him now (he’s spoken to more than 50), he’s careful:
- He explains it worked for him, but might not work for them
- He encourages going without expectation
- He frames it as “knowing you tried everything,” not a guaranteed fix
That’s responsible guidance from someone who understands how fragile hope can become when it’s under financial pressure.
What changed fast (and what stayed improved 18 months later)
Andrew’s report of early changes is striking not because it proves causality, but because it describes specific, functional shifts:
Cognitive fatigue and sensory overload
He noticed cognitive fatigue dial down immediately. He still experiences it, but it takes far more to trigger now.
The most vivid example: on the way to the clinic, he used an eye mask, noise-cancelling headphones, and had medication ready for overload. On the return flight 24 hours later, he didn’t need any of it. He stood in the airport like any other traveler.
Pain and cramping
A persistent cramp in his right calf eased significantly.
Emotional regulation
He noticed improvement in emotional control, something many stroke survivors quietly struggle with and often feel ashamed about.
Hand function and fine motor control
His right hand went from feeling like it moved “in molasses” to loosening up.
And here’s where the “18 months on” part becomes powerful: Andrew recently discovered he could play scales on his clarinet again, covering holes with independent finger movement, something he hadn’t been able to do since the stroke.
That’s not framed as: “etanercept did this.” It’s framed as: recovery kept unfolding.
“Your stroke recovery doesn’t stop. There’s no end date.”
The PESTO trial: when research challenges your story
Then came the PESTO trial results, which (as discussed in your episode) reported that etanercept was not more effective than placebo in the studied group.
This is where Andrew’s story gets even more human.
He didn’t just shrug it off.
He described feeling guilt, even fraudulence, because he couldn’t reconcile the research headline with his lived experience.
That response is deeply relatable: when something helps you, and others don’t get the same outcome, it can feel like survivor’s guilt, especially when people have spent enormous money and emotional energy.
A careful theory: the blood–brain barrier question
In your conversation, Bill raises a hypothesis, not a proven conclusion that deserves careful attention:
If etanercept struggles to cross the blood–brain barrier in general, could certain people have a more permeable barrier due to factors like stroke, surgery, or radiation therapy (which Andrew had)?
Andrew himself wonders if radiation could be part of his “why.”
This isn’t a sales pitch. It’s a research direction, a possible explanation for why outcomes might vary so dramatically between people.
If that line of thinking ever becomes clinically actionable, it could change the whole decision-making process for survivors, because the question would shift from “roll the dice” to “are you likely to be a candidate?”
What a stroke survivor can take from this without being sold to
If you’re reading this because you’re considering a stroke etanercept injection, here are the grounded takeaways from Andrew’s 18-month update:
- Recovery can continue for years. Don’t let a timeline kill your momentum.
- Treatments don’t have to be “proven” to feel meaningful, but meaning isn’t the same as certainty.
- Hope needs guardrails. Don’t stake your whole future on one intervention.
- If you pursue something controversial, protect your mindset. Go in informed, realistic, and supported.
- You deserve respect, not ridicule, for wanting your life back.
If you want ongoing encouragement and tools to navigate recovery (and the emotional complexity that comes with it), Bill’s work is built for that:
- Book: recoveryafterstroke.com/book
- Patreon: patreon.com/recoveryafterstroke
This blog is for informational purposes only and does not constitute medical advice. Please consult your doctor before making any changes to your health or recovery plan.
Andrew’s 18-Month Etanercept Update: Fatigue, Function, and What the Research Says
18 months later, Andrew shares what improved after etanercept fatigue, function, and the tough questions raised by the PESTO trial.
Highlights:
00:00 Introduction and Background
06:15 Exploring Treatment Options
08:59 Stroke Etanercept Injection And It’s Impact
12:14 Research Findings and Controversies
17:59 Conversations with Other Survivors
23:26 Reflections on Treatment and Guilt
